Select Your Location:
Global
France
Italy

Pipeline

We are pursuing a broad and deep pipeline with the potential to address 80 percent of the world’s cancers by incidence. Explore our oncology-focused pipeline, dedicated to addressing the most pressing challenges in cancer care.

Area of interest

Pipeline

We are pursuing a broad and deep pipeline with the potential to address 80 percent of the world’s cancers by incidence. Explore our oncology-focused pipeline, dedicated to addressing the most pressing challenges in cancer care.

Area of interest
Download full pipeline
Area of interest
Area of interest
Planned
Ongoing
Completed
Filter

Filters

Filter

Search

You can either apply the filter or type directly into the search bar.

You can either apply the filter or type directly into the search bar.

The pipeline is updated quarterly. Last updated May 2025.

Safety and efficacy have not been established for investigational products and/or uses.

*Approved in at least one major market, such as the USA, EU, China and/or Japan.

**Phase 3 Confirmatory

References

  1. Amgen collaboration; BeOne has development and commercialization rights in China.
  2. Giffin MJ, Cooke K, Lobenhofer EK, et al. AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer. Clin Cancer Res.
    2021;27:1526-1537.
  3. Baeuerle PA, Kufer P, Bargou R. BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther. 2009;11:22-30.
  4. Ahn MJ, Cho BC, Felip E, et al. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. N Engl J Med. 2023;389:2063-2075.
  5. Rojo F, Corassa M, Mavroudis D, et al. International real-world study of DLL3 expression in patients with small cell lung cancer. Lung Cancer. 2020;147:237-243.
  6. Zymeworks/Jazz collaboration; BeOne has exclusive development and commercialization rights in Asia (except Japan), Australia and New Zealand.
  7. Ensem collaboration; BeOne has global rights.
  8. CSPC collaboration.
  9. O’Bryan JP, et al. Pharmacol Res 2019;139:503-511.
  10. Zhu C, et al. Mol Cancer 2022;21:159.
  11. Izumi M, et al. J Thorac Dis 2020;12:3776-3784.
  12. DualityBio collaboration; BeOne has global clinical, manufacturing and commercialization rights.
  13. Kelly W, Danila D, Lin C, et al. Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. Cancer Discovery. 2024;14
    (1): 76–89.
  14. Kelly W, Danila D, Lin C, et al. 1765O Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Annals of Oncology. 2023;34: S953-S954.